Innovent Biologics stock falls 2.71 percent before ESMO data

Innovent Biologics stock (ISIN KYG4818G1010) was trading at HKD 100.60 on HKEX on September 24, 2026, down 2.71 percent from the prior close of HKD 103.40. The company has scheduled clinical presentations for five programs at the 2026 ESMO Annual Meeting, according to PR Newswire on September 23, 2026.

Five programs reach ESMO

The planned data cover IBI363, IBI343, IBI3001, IBI354 and TYVYT. The presentation schedule runs from October 23 to October 27, 2026, in Madrid, giving the pipeline a defined near-term disclosure date.

IBI343 is the most prominent item in the announcement because results from the G-HOPE-001 Phase 3 trial were accepted as a late-breaking abstract for oral presentation. That places a registrational-stage asset at the center of the upcoming medical conference.

Stock remains below yearly peak

The September 24 price of HKD 100.60 sits HKD 12.10 below the 52-week high of HKD 112.70, a gap of 10.74 percent. It is also HKD 31.05 above the 52-week low of HKD 69.55, showing that the current quote remains materially closer to the top of its yearly range than to the bottom.

Innovent's market capitalization stood at HKD 175,136,552,000 on September 24, 2026. The combination of a defined clinical-data date and a price below the yearly high makes the October disclosures the next measurable test for the stock's valuation.

HKD 100.60 sets the reference

Innovent Biologics stock was trading at HKD 100.60 on HKEX on September 24, 2026. The daily comparison is 2.71 percent below HKD 103.40, while the 52-week range extends from HKD 69.55 to HKD 112.70.

More news and analyses on Innovent Biologics stock